Cambrex is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa. The $50m investment is designed to meet the growing demand for small molecule drug substance development and manufacturing.
It will be the sixth major investment that Cambrex has made at the site in the past eight years to support customers in mid-scale, large-scale and highly potent small molecule API manufacturing.
The expansion, which is aimed to be operational in early 2022, will add 3 large-scale manufacturing work centres and 1 mid-scale work centre to the facility in Iowa, increasing the site’s capacity by 30 percent. When completed, the Charles City site will employ more than 400 people.
“Small molecule manufacturing demand has been growing consistently over recent years, and this investment will enable Cambrex to continue to capitalise on this growth, further strengthening our position as a market-leading CDMO,” said Joe Nettleton, President of Cambrex’s Drug Substance Business Unit. He added, “This expansion in the US for API manufacturing capacity comes at a time when our customers increasingly require high-quality partners to ensure reliable supply chains within the pharmaceutical sector.
Cambrex’s Charles City facility is located on a 45-acre site, and as part of the company’s drug substance business unit, manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
